
Regenxbio Inc RGNX.O:
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
REGENXBIO INC - FAVORABLE SAFETY PROFILE CONTINUES WITH NO SERIOUS ADVERSE EVENTS OBSERVED IN RGX-202 TRIAL
REGENXBIO INC - PIVOTAL TRIAL EXPECTED TO SUPPORT BLA SUBMISSION USING ACCELERATED APPROVAL PATHWAY IN MID-2026
REGENXBIO INC -EXPECTS TO SHARE TOP-LINE DATA IN FIRST HALF OF 2026